Lyell Immunopharma, Inc. (LYEL) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 2K | 6K | 15K | 8K | 7K | 11K | 34K | 13K | 3K | 13K | 25K | 27K |
| Revenue Growth % | -71.43% | -45.45% | -55.88% | -38.46% | 133.33% | -15.38% | 36% | -51.85% | -95.38% | -99.97% | 733.33% | -99.92% |
| Cost of Goods Sold | 2.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.06M | 5.1M | 4.54M |
| COGS % of Revenue | 116600% | - | - | - | - | - | - | - | - | 38900% | 20416% | 16811.11% |
| Gross Profit | -2.33M | 6K | 15K | 8K | 7K | 11K | 34K | 13K | 3K | -5.04M | -5.08M | -4.51M |
| Gross Margin % | -116500% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | -38800% | -20316% | -16711.11% |
| Gross Profit Growth % | -33385.71% | -45.45% | -55.88% | -38.46% | 133.33% | 100.22% | 100.67% | 100.29% | 100.06% | -111.52% | -21.83% | -114.1% |
| Operating Expenses | 43.83M | 61.32M | 37.27M | 47.15M | 57.37M | 201.16M | 50.54M | 51.54M | 55.58M | 54.79M | 55.5M | 61.36M |
| OpEx % of Revenue | 2191350% | 1021966.67% | 248453.33% | 589350% | 819628.57% | 1828709.09% | 148644.12% | 396469.23% | 1852600% | 421430.77% | 221992% | 227248.15% |
| Selling, General & Admin | 9.55M | 10.62M | 10.69M | 9.79M | 14.05M | 14.52M | 11.77M | 12.26M | 13.49M | 13.17M | 15.51M | 19.03M |
| SG&A % of Revenue | 477750% | 176933.33% | 71246.67% | 122325% | 200657.14% | 132018.18% | 34614.71% | 94276.92% | 449800% | 101284.62% | 62028% | 70481.48% |
| Research & Development | 36.6M | 52.2M | 28.17M | 34.86M | 43.45M | 48.67M | 39.5M | 40.26M | 43.17M | 41.62M | 39.99M | 42.33M |
| R&D % of Revenue | 1830200% | 869983.33% | 187813.33% | 435712.5% | 620671.43% | 442436.36% | 116176.47% | 309700% | 1439133.33% | 320146.15% | 159964% | 156766.67% |
| Other Operating Expenses | -1000K | -1000K | -1000K | 1000K | -119K | 1000K | -730K | -976K | -1000K | 0 | 0 | 0 |
| Operating Income | -46.16M | -61.31M | -37.25M | -47.14M | -57.37M | -201.15M | -50.51M | -51.53M | -55.58M | -59.83M | -60.58M | -65.87M |
| Operating Margin % | -2307850% | -1021866.67% | -248353.33% | -589250% | -819528.57% | -1828609.09% | -148544.12% | -396369.23% | -1852500% | -460230.77% | -242308% | -243959.26% |
| Operating Income Growth % | 19.54% | 69.52% | 26.24% | 8.52% | -3.22% | -236.2% | 16.63% | 21.77% | 13.77% | -274.08% | 9.16% | -77.87% |
| EBITDA | -43.83M | -58.91M | -34.69M | -44.01M | -53.93M | -196.12M | -45.83M | -46.63M | -50.55M | -54.77M | -55.47M | -61.33M |
| EBITDA Margin % | -2191250% | -981916.67% | -231246.67% | -550062.5% | -770371.43% | -1782918.18% | -134779.41% | -358669.23% | -1685033.33% | -421330.77% | -221892% | -227148.15% |
| EBITDA Growth % | 18.73% | 69.96% | 24.31% | 5.62% | -6.68% | -258.06% | 17.39% | 23.97% | 14.93% | -380.38% | 11.27% | -84.16% |
| D&A (Non-Cash Add-back) | 2.33M | 2.4M | 2.57M | 3.13M | 3.44M | 5.03M | 4.68M | 4.9M | 5.02M | 5.06M | 5.1M | 4.54M |
| EBIT | -46.16M | -61.31M | -38.85M | -45.7M | -57.37M | -62.67M | -50.51M | -51.53M | -55.58M | -52.93M | -50.85M | -63.89M |
| Net Interest Income | 2.19M | 2.68M | 3.27M | 3.28M | 3.86M | 4.92M | 5.96M | 6.36M | 6.82M | 7.08M | 6.61M | 5.26M |
| Interest Income | 2.19M | 2.68M | 3.27M | 3.28M | 3.86M | 4.92M | 5.96M | 6.36M | 6.82M | 7.08M | 6.61M | 5.26M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 22M | -79.41M | -1.59M | 4.46M | 5.17M | 9.21M | 5.92M | 5.72M | -5.09M | 6.9M | 9.72M | 1.98M |
| Pretax Income | -24.15M | -140.72M | -38.85M | -42.68M | -52.2M | -191.94M | -44.58M | -45.81M | -60.67M | -52.93M | -50.85M | -63.89M |
| Pretax Margin % | -1207650% | -2345383.33% | -258973.33% | -533550% | -745642.86% | -1744863.64% | -131126.47% | -352376.92% | -2022233.33% | -407153.85% | -203412% | -236629.63% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -24.15M | -140.72M | -38.85M | -42.68M | -52.2M | -191.94M | -44.58M | -45.81M | -60.67M | -52.93M | -50.85M | -63.89M |
| Net Margin % | -1207650% | -2345383.33% | -258973.33% | -533550% | -745642.86% | -1744863.64% | -131126.47% | -352376.92% | -2022233.33% | -407153.85% | -203412% | -236629.63% |
| Net Income Growth % | 53.73% | 26.68% | 12.87% | 6.82% | 13.96% | -262.62% | 12.33% | 28.3% | 9.4% | -530.34% | 27.62% | -75.89% |
| Net Income (Continuing) | -24.15M | -140.72M | -38.85M | -42.68M | -52.2M | -191.94M | -44.58M | -45.81M | -60.67M | -52.93M | -50.85M | -63.89M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.10 | -6.62 | -2.13 | -2.89 | -0.18 | -0.72 | -0.17 | -0.18 | -0.24 | -0.21 | -0.20 | -0.26 |
| EPS Growth % | -511.11% | -819.44% | -1152.94% | -1510.93% | 24.56% | -244.33% | 16.01% | 29.76% | 11.07% | -522.32% | 28.46% | -73.15% |
| EPS (Basic) | -1.10 | -10.86 | -2.13 | -2.89 | -0.18 | -0.72 | -0.17 | -0.18 | -0.24 | -0.21 | -0.20 | -0.26 |
| Diluted Shares Outstanding | 21.88M | 17.09M | 18.27M | 14.79M | 14.75M | 13.33M | 12.82M | 12.77M | 12.71M | 12.65M | 12.57M | 12.51M |
| Basic Shares Outstanding | 21.88M | 17.09M | 18.27M | 14.79M | 14.75M | 13.33M | 12.82M | 12.77M | 12.71M | 12.65M | 12.57M | 12.51M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |